Scott Rowlinson Ph.D Overview

  • Primary Position
  • Vice President

Scott Rowlinson Ph.D General Information

Biography

Dr. Scott Rowlinson serves as Vice President, Research & Development at Aeglea BioTherapeutics Holdings. Dr. Rowlinson holds a PhD in Physiology and Biochemistry and was recruited from Eli Lilly and Company. He has a proven track record of scientific productivity in biologics drug discovery and development, and has demonstrated leadership in coordinating drug discovery to clinical development. These efforts led to 3 successful IND submissions, the most advanced being in Phase 2 development. Dr. Rowlinson has a wealth of experience in the broader concepts of biomolecule drug development, including uncovering factors involved in clinical portfolio attrition, and optimal integration of companion diagnostic development and drug development.

Contact Information

Primary Position
Vice President, Aeglea BioTherapeutics
Gender
Male
Email
sc

Scott Rowlinson Ph.D FAQs

  • Who is Scott Rowlinson Ph.D?

    Dr. Scott Rowlinson serves as Vice President, Research & Development at Aeglea BioTherapeutics Holdings.

  • How much does Scott Rowlinson Ph.D typically invest?

    Scott Rowlinson Ph.D's median deal size is .

  • What is Scott Rowlinson Ph.D’s main position?

    Scott Rowlinson Ph.D’s primary position is Vice President.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »